2-[tert-Butyl(dimethyl)silyl]oxy-6-chloro-3-isopropyl-4-(2,2,2-trifluoroethoxy)quinoline | 345913-68-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-[tert-Butyl(dimethyl)silyl]oxy-6-chloro-3-isopropyl-4-(2,2,2-trifluoroethoxy)quinoline
• 英文别名: Tert-butyl-[6-chloro-3-propan-2-yl-4-(2,2,2-trifluoroethoxy)quinolin-2-yl]oxy-dimethylsilane
• CAS: 345913-68-0
• 化学式: C₂₀H₂₇ClF₃NO₂Si
• 分子量: 433.974
• InChiKey: UKPFOYKGPDABKM-UHFFFAOYSA-N

物化性质

• 沸点：
  418.7±45.0 °C(Predicted)
• 密度：
  1.148±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.34
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-[tert-Butyl(dimethyl)silyl]oxy-6-chloro-3-isopropyl-4-(2,2,2-trifluoroethoxy)quinoline 在 acidic resin AG 50W-X₄ 、 lithium 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 1.5h， 生成 6-Chloro-4-[(2-Cyclopropylethynyl)oxy]-3-isopropyl-2(1H)-quinolinone
  参考文献：
  名称：

  Design of Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase with Improved Drug Resistance Properties. 2.

  摘要：

  HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs) are part of the combination therapy currently used to treat HIV infection. The features of a new NNRTI drug for HIV treatment must include selective potent activity against both wild-type virus as well as against mutant virus that have been selected by use of current antiretroviral treatment regimens. Based on analogy with known HIV-1 NNRTI inhibitors and modeling studies utilizing the X-ray crystal structure of inhibitors bound in the HIV-1 RT, a series of substituted 2-quinolones was synthesized and evaluated as HIV-1 inhibitors.

  DOI：

  10.1021/jm040072r
• 作为产物：
  描述：

  异丙基丙二酸二乙酯 在 sodium hydride 、 三乙胺 作用下， 以 二苯醚 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-[tert-Butyl(dimethyl)silyl]oxy-6-chloro-3-isopropyl-4-(2,2,2-trifluoroethoxy)quinoline
  参考文献：
  名称：

  Design of Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase with Improved Drug Resistance Properties. 2.

  摘要：

  HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs) are part of the combination therapy currently used to treat HIV infection. The features of a new NNRTI drug for HIV treatment must include selective potent activity against both wild-type virus as well as against mutant virus that have been selected by use of current antiretroviral treatment regimens. Based on analogy with known HIV-1 NNRTI inhibitors and modeling studies utilizing the X-ray crystal structure of inhibitors bound in the HIV-1 RT, a series of substituted 2-quinolones was synthesized and evaluated as HIV-1 inhibitors.

  DOI：

  10.1021/jm040072r

文献信息

• Quinolone compounds for use in treating viral infections
  申请人：——

  公开号：US20030069271A1

  公开（公告）日：2003-04-10

  The present invention relates to quinolone compounds and their use in the treatment of viral infections.

  本发明涉及喹诺酮化合物及其在治疗病毒感染中的应用。